

Panion will not renew Letter of Intent with GeneQuine

The board of directors for Panion Animal Health AB decided at their meeting of 4 December 2017 to focus Panion's efforts on the development of the epilepsy project. This means that we will no longer pursue the dialogue and cooperation with GeneQuine Biotherapeutics GmbH with regards to their veterinary gene therapy projects. The mutually agreed Letter of Intent will therefore not be sought renewed or extended upon expiry on the 31 December 2017. The decision was

taken for business reasons with the aim to focus on the opportunities that best fit with Panion's strategic plans and have the potential to create the best future value for Panion's shareholders.

"Panion will continue to evaluate human medicines projects that may carry great potential for development in veterinary medicine" says Anja Holm, CEO of Panion.

For further information, please contact:

Anja E. H. Holm, CEO | +45-22 94 66 00
anja.holm@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at AktieTorget.

Panion Animal Health AB

Frykholmogatan 11, 281 31 Hässleholm, Sweden
info@panion-animalhealth.com

[linkedin.com/company/panion-animalhealth](https://www.linkedin.com/company/panion-animalhealth) 
twitter.com/panionanihealth 
panion-animalhealth.com/newsletter 
panion-animalhealth.com 